含贝达喹啉全口服短程化疗治疗耐多药肺结核疗效及安全性观察临床研究  

Efficacy and safety of total oral short-course chemotherapy containing Bedaquinoline in treatment of patients with multidrug resistant pulmonary tuberculosis

作　　者：李静虹[1] 刘红莲[2] 宗凯仁 周燕红[4] 钟诚[3] LI Jinghong;LIU Honglian;ZONG Kairen;ZHOU Yanhong;ZHONG Cheng(Department of Infectious Diseases,Jiangxi Provincial Chest Hospital,Nanchang 330006,China)

机构地区：[1]江西省胸科医院感染性疾病科,江西南昌330006 [2]江西省胸科医院科教科,江西南昌330006 [3]江西省胸科医院结核二科,江西南昌330006 [4]江西省胸科医院结核病综合防治科,江西南昌330006

出　　处：《陕西医学杂志》2024年第7期958-961,共4页Shaanxi Medical Journal

基　　金：中央引导地方科技发展基金资助项目(20221ZDG020069);江西省应用研究培育计划项目(20212BAG70015)。

摘　　要：目的:探讨含贝达喹啉全口服短程化疗治疗耐多药肺结核患者的疗效及安全性。方法:选择100例耐多药肺结核患者,以随机数字表法将其分为对照组(WHO长疗程方案)50例和观察组(含贝达喹啉全口服短程方案)50例。比较两组患者痰培养阴转率、治愈率,并行胸部CT检查,观察病灶及空洞变化,并记录不良反应率发生情况。结果:观察组24周阴转率为84.00%(41/50)高于对照组74.00%(27/50),观察组36周时病灶吸收及空洞改善好于对照组(P<0.05)。观察组终点治愈率76.00%(38/50)高于对照组治愈率52.00%(26/50)(P<0.05)。对照组治疗过程中共出现不良反应84例次,观察组共出现不良反应69例次,两组不良反应发生情况比较,差异有统计学意义(P<0.05)。结论:含贝达喹啉全口服短程化疗方案治疗耐多药肺结核疗程短、治愈率高、安全性良好。Objective:To investigate the efficacy and safety of total oral short-course chemotherapy containing Bedaquinoline in the treatment of multi-drug resistant pulmonary tuberculosis.Methods:A total of 100 patients with MDR-TB were selected and divided into control group(WHO long-course regimen,50 cases)and observation group(including Bedaquinoline short-course regimen,50 cases)by random number table method.The negative conversion rate and cure rate of sputum culture were compared between two group,and the changes of lesions and cavities were observed by chest CT,and the occurrence rate of adverse reactions was recorded.Results:The negative conversion rate at 24 weeks in the observation group was 84.00%(41/50),higher than 74.00%(27/50)in the control group.The improvement of lesion absorption and cavity in the observation group at 36 weeks was better than that in the control group(P<0.05).The cure rate of observation group was 76.00%(38/50),higher than 52.00%(26/50)of control group(P<0.05).There were a total of 84 adverse reactions in the control group and 69 adverse reactions in the observation group.There was statistical significance in the occurrence of adverse reactions between the two groups(P<0.05).Conclusion:Total oral short-course chemotherapy containing Bedaquinoline has short course of treatment,high cure and good safety.

关 键 词：耐多药肺结核 贝达喹啉 短程化疗 疗效 不良反应 安全性 

分 类 号：R521[医药卫生—内科学]